Cargando…

Current strategies to treat tuberculosis

Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. TB control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and human imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Podany, Anthony T., Swindells, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089133/
https://www.ncbi.nlm.nih.gov/pubmed/27853505
http://dx.doi.org/10.12688/f1000research.7403.1
_version_ 1782464222329831424
author Podany, Anthony T.
Swindells, Susan
author_facet Podany, Anthony T.
Swindells, Susan
author_sort Podany, Anthony T.
collection PubMed
description Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. TB control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and human immunodeficiency virus (HIV) epidemics, and the emergence of drug-resistant TB. After a long period of neglect, there is now significant progress in the development of novel treatment regimens for TB. Focusing on treatment for active disease, we review pathways to TB regimen development and the new and repurposed anti-TB agents in clinical development.
format Online
Article
Text
id pubmed-5089133
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-50891332016-11-15 Current strategies to treat tuberculosis Podany, Anthony T. Swindells, Susan F1000Res Review Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. TB control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and human immunodeficiency virus (HIV) epidemics, and the emergence of drug-resistant TB. After a long period of neglect, there is now significant progress in the development of novel treatment regimens for TB. Focusing on treatment for active disease, we review pathways to TB regimen development and the new and repurposed anti-TB agents in clinical development. F1000Research 2016-10-26 /pmc/articles/PMC5089133/ /pubmed/27853505 http://dx.doi.org/10.12688/f1000research.7403.1 Text en Copyright: © 2016 Podany AT and Swindells S http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Podany, Anthony T.
Swindells, Susan
Current strategies to treat tuberculosis
title Current strategies to treat tuberculosis
title_full Current strategies to treat tuberculosis
title_fullStr Current strategies to treat tuberculosis
title_full_unstemmed Current strategies to treat tuberculosis
title_short Current strategies to treat tuberculosis
title_sort current strategies to treat tuberculosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089133/
https://www.ncbi.nlm.nih.gov/pubmed/27853505
http://dx.doi.org/10.12688/f1000research.7403.1
work_keys_str_mv AT podanyanthonyt currentstrategiestotreattuberculosis
AT swindellssusan currentstrategiestotreattuberculosis